195 related articles for article (PubMed ID: 28002639)
1. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
Bell GC; Caudle KE; Whirl-Carrillo M; Gordon RJ; Hikino K; Prows CA; Gaedigk A; Agundez J; Sadhasivam S; Klein TE; Schwab M
Clin Pharmacol Ther; 2017 Aug; 102(2):213-218. PubMed ID: 28002639
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Clin Pharmacol Ther; 2018 Feb; 103(2):349. PubMed ID: 29313967
[No Abstract] [Full Text] [Related]
6. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke.
Simon T; Danchin N
Circulation; 2017 Jan; 135(1):34-37. PubMed ID: 28028061
[No Abstract] [Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.
Gonsalves SG; Dirksen RT; Sangkuhl K; Pulk R; Alvarellos M; Vo T; Hikino K; Roden D; Klein TE; Poler SM; Patel S; Caudle KE; Gordon R; Brandom B; Biesecker LG
Clin Pharmacol Ther; 2019 Jun; 105(6):1338-1344. PubMed ID: 30499100
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Phillips EJ; Sukasem C; Whirl-Carrillo M; Müller DJ; Dunnenberger HM; Chantratita W; Goldspiel B; Chen YT; Carleton BC; George AL; Mushiroda T; Klein T; Gammal RS; Pirmohamed M
Clin Pharmacol Ther; 2018 Apr; 103(4):574-581. PubMed ID: 29392710
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
Desta Z; Gammal RS; Gong L; Whirl-Carrillo M; Gaur AH; Sukasem C; Hockings J; Myers A; Swart M; Tyndale RF; Masimirembwa C; Iwuchukwu OF; Chirwa S; Lennox J; Gaedigk A; Klein TE; Haas DW
Clin Pharmacol Ther; 2019 Oct; 106(4):726-733. PubMed ID: 31006110
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ; Thomas CD; Barbarino J; Desta Z; Van Driest SL; El Rouby N; Johnson JA; Cavallari LH; Shakhnovich V; Thacker DL; Scott SA; Schwab M; Uppugunduri CRS; Formea CM; Franciosi JP; Sangkuhl K; Gaedigk A; Klein TE; Gammal RS; Furuta T
Clin Pharmacol Ther; 2021 Jun; 109(6):1417-1423. PubMed ID: 32770672
[TBL] [Abstract][Full Text] [Related]
15. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN; Hicks TL
J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework.
Plumpton CO; Pirmohamed M; Hughes DA
Clin Pharmacol Ther; 2019 Jun; 105(6):1429-1438. PubMed ID: 30466189
[TBL] [Abstract][Full Text] [Related]
18. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.
Roden DM; Van Driest SL; Mosley JD; Wells QS; Robinson JR; Denny JC; Peterson JF
Clin Pharmacol Ther; 2018 May; 103(5):787-794. PubMed ID: 29377064
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
[TBL] [Abstract][Full Text] [Related]
20. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT
Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
